— Know what they know.
Not Investment Advice
Also trades as: 0IDA.L (LSE) · $vol 0M

DVAX NASDAQ

Dynavax Technologies Corporation
1W: +38.2% 1M: +43.6% 3M: +49.6% 1Y: +18.3% 3Y: +42.5% 5Y: +174.6%
$15.50
Last traded 2025-12-31 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $1.8B mcap · 100M float · 3.15% daily turnover · Short 43% of daily vol

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$277M +19.4% ▲
5Y CAGR: +51.1%
Gross Profit
$228M +25.1% ▲
5Y CAGR: +70.5%
Operating Income
-$4M +88.9% ▲
Net Income
$27M +527.4% ▲
EPS (Diluted)
$0.20 +503.2% ▲
EBITDA
$46M +372.8% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
Revenue$47M$439M$723M$232M$277M
YoY Growth+32.2%+844.0%+64.5%-67.9%+19.4%
Cost of Revenue$14M$174M$262M$50M$49M
Gross Profit$33M$266M$461M$182M$228M
Gross Margin70.1%60.5%63.7%78.4%82.2%
R&D Expenses$29M$32M$47M$55M$62M
SG&A Expenses$79M$100M$131M$153M$170M
Operating Expenses$108M$131M$177M$219M$232M
Operating Income-$75M$134M$284M-$37M-$4M
Operating Margin-161.6%30.6%39.2%-15.9%-1.5%
Interest Expense$19M$11M$7M$7M$7M
Income Before Tax-$75M$78M$294M-$4M$31M
Tax Expense$0$808K$1M$2M$4M
Net Income-$75M$77M$293M-$6M$27M
Net Margin-161.6%17.5%40.6%-2.8%9.9%
EPS (Diluted)$-0.78$0.57$1.97$-0.05$0.20
EBITDA-$47M$96M$308M$10M$46M
Shares Outstanding101M133M151M129M133M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms